Guest guest Posted December 15, 2009 Report Share Posted December 15, 2009 " According to a duo of " ASCO 2009 presentations, some patients are not being dose escalated on imatinib prior to switching to dasatinib (Sprycel). Also, switching to dasatinib was found to be associated with more adverse events than dose escalation of imatinib. These studies give us a window on real-world clinical practice and suggest that we need to make greater efforts to educate patients and providers on how to follow NCCN guidelines,” said the senior author of both posters, , MD, director of medical oncology at Dana-Farber Cancer Center and professor of medicine at Harvard Medical School, both in Boston. " More on this subject can be found at: http://tinyurl.com/ydv5u2x FYI, Lottie Duthu Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.